Compare ANNX & EQBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANNX | EQBK |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.5M | 932.4M |
| IPO Year | 2020 | 2015 |
| Metric | ANNX | EQBK |
|---|---|---|
| Price | $5.79 | $45.91 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | $16.50 | ★ $51.33 |
| AVG Volume (30 Days) | ★ 2.2M | 101.9K |
| Earning Date | 05-11-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 1.59% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.23 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $74.58 |
| Revenue Next Year | $16,320.74 | $5.11 |
| P/E Ratio | ★ N/A | $36.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $36.04 |
| 52 Week High | $7.18 | $50.07 |
| Indicator | ANNX | EQBK |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 55.91 |
| Support Level | $4.79 | $44.41 |
| Resistance Level | $6.56 | $48.05 |
| Average True Range (ATR) | 0.29 | 0.95 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 8.43 | 66.94 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 77 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.